Skip to main content
. Author manuscript; available in PMC: 2022 Apr 11.
Published in final edited form as: Science. 2022 Feb 3;375(6583):877–884. doi: 10.1126/science.abl5447

Table 1. Summary of prospectively predicted TCRs from four patient tumor TILs to identify antitumor, neoantigen-reactive TCRs using the NeoTCR gene signature.

“Tumor” refers to direct organoid or PDX reactivity. NeoAg, neoantigen; TAA, tumor-associated antigen.

Prospective prediction of TCRs reactive with tumor
CD8 CD4 All
Tumor Tested Tumor and
NeoAg-reactive
NeoAg only Tumor only Total Tested NeoAg-reactive TAA-reactive Tumor only Total Tested Total %
4393 8 4 0 3 7 6 3 1 0 4 14 11 79
4394 12 2 0 1 3 0 0 0 0 0 12 3 25
4400 15 0 0 9 9 14 5 0 0 5 29 14 48
4421 7 3 2 2 7 11 2 0 0 2 18 9 50
All 42 9 2 15 26
61.9%
31 10 1 0 11
35.4%
73 37 50.7